AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8256902
Drug: MDI albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI albuterol (100 puffs, 9 mg)
Trial: 3236320
Drug: Indapamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5 mg/day)
Trial: 22544004
Drug: Open-label olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label olanzapine treatment (2.5 or 5 mg/d, increased up to 20 mg/d in study 1 or 15 mg/d in study 2)
Trial: 22544004
Drug: Open-label olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label olanzapine treatment after placebo during the acute phase
Trial: 22544004
Drug: Open-label olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label olanzapine treatment after olanzapine during the acute phase
Trial: 18922335
Drug: Pillar palate
RxNorm normalized name: palmate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pillar palate implants
Trial: 12458116
Drug: Combined antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiemetic strategy including nursing intervention program (increased access to support and increased information) and antiemetics based on high‐dose metoclopramide and dexamethasone
Trial: 12458116
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic treatment during the 1980s
Trial: 8081005
Drug: CY-TBI (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY-TBI (60 mg/kg cyclophosphamide on each of 2 successive days followed by 6 fractions of total body irradiation each of 2.0 Gy)
Trial: 8081005
Drug: BU-CY (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BU-CY (16 mg/kg busulfan over 4 days followed by 60 mg/kg cyclophosphamide on each of 2 successive days)
Trial: 2526824
Drug: Acitretin 10
RxNorm normalized name: acitretin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin 10 mg/day
Trial: 2526824
Drug: Acitretin 75
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin 75 mg/day
Trial: 2127045
Drug: Xylitol infusion
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol infusion
Trial: 12139223
Drug: Halofantrine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine (500 mg)
Trial: 12139223
Drug: Co-artemether (80/480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-artemether (80/480 mg)
Trial: 8588061
Drug: 75-100 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-100 mg/day amitriptyline (n=16)
Trial: 8588061
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day amineptine (n=10)
Trial: 8588061
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with classic tricyclic antidepressants
Trial: 8588061
Drug: Dopaminergic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic drugs
Trial: 6817270
Drug: 1% glycopyrrolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glycopyrrolate roll-on lotion and cream
Trial: 6817270
Drug: Topical scopolamine
RxNorm normalized name: scopolamine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical scopolamine (solution and cream)
Trial: 6817270
Drug: Glycopyrrolate (roll-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (roll-on lotion, solution, and cream)
Trial: 31468214
Drug: Fluid-restrictive vasopressor-dominated
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid-restrictive vasopressor-dominated hemodynamic support (FRV) with norepinephrine concentration of 0.065±0.020 μg/kg/min
Trial: 31468214
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid administration (LFA) with fluid administration of 5.1±2.2 ml/kg/h
Trial: 31617141
Drug: Stiripentol as
RxNorm normalized name: stiripentol
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stiripentol as adjunctive therapy
Trial: 16313817
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel plus carboplatin
Trial: 7775623
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (Estraderm‐TTS 100)
Trial: 7775623
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen (Premarin, 1.25 mg)
Trial: 2310655
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g day-1 acetylsalicylic acid
Trial: 2310655
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g day-1 paracetamol
Trial: 2310655
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g day-1 acetylsalicylic acid and 1.5 g day-1 paracetamol (combination)
Trial: 2310655
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g day-1 acetylsalicylic acid (separated by washout phases)
Trial: 2310655
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four drug schedules
Trial: 6184562
Drug: VER (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VER (80 mg t.i.d.)
Trial: 6184562
Drug: NIF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIF (10 mg t.i.d.)
Trial: 6184562
Drug: VER (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VER (160 mg t.i.d.)
Trial: 6184562
Drug: VER (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VER (80 mg t.i.d.) and NIF (10 mg t.i.d.)
Trial: 30849076
Drug: Open-loop insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-loop insulin delivery
Trial: 25901546
Drug: Aerosolized albuterol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized albuterol
Trial: 9110517
Drug: Integrated mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated mental health and substance abuse treatment program
Trial: 9110517
Drug: Standard psychiatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard psychiatric hospital treatment
Trial: 30430201
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment other than the prescribed medication (Control)
Trial: 28399981
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors plus insulin
Trial: 26370528
Drug: Protective group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective group (Group P) - tidal volume of 6 mL/kg, FiO2 of 80%, PEEP of 5 cm H2O
Trial: 26370528
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (Group C) - tidal volume of 8 mL/kg, FiO2 of 100%
Trial: 20824894
Drug: Saffron 60
RxNorm normalized name: SAFFRON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron 60 mg/day for 26 weeks
Trial: 15624283
Drug: Docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic acid (DHA) 1.2 g/d
Trial: 11577791
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled corticosteroids
Trial: 9267685
Drug: Sertindole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole administered as tablets after fasting
Trial: 9267685
Drug: Sertindole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole administered as tablets with food
Trial: 9267685
Drug: Sertindole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole administered as tablets with Maalox (antacid)
Trial: 9267685
Drug: Sertindole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole administered as solution
Trial: 9267685
Drug: Sertindole administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole administered as tablets under fasting conditions
Trial: 1980611
Drug: Anticholinergic medication
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic medication
Trial: 7905226
Drug: No antiparkinsonian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiparkinsonian drug
Trial: 28627275
Drug: 4-week mixed-modality
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week mixed-modality supervised exercise program (4 times a week, twice a day)
Trial: 15142103
Drug: Mandibular implant‐retained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular implant‐retained overdentures
Trial: 24417762
Drug: Implant‐supported fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant‐supported fixed partial dentures (FPDs)
Trial: 12807998
Drug: Ibuprofen (Cmax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Cmax >50 microg/ml)
Trial: 12807998
Drug: Ibuprofen (Cmax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Cmax <50 microg/ml)
Trial: 11212064
Drug: Atenolol and
RxNorm normalized name: atenolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol and hydralazine (as secondary and tertiary drugs)
Trial: 8857564
Drug: Tacrolimus high
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus high zone (0.6-1.2 ng/ml) in Primary Biliary Cirrhosis study group
Trial: 8857564
Drug: Tacrolimus low
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus low zone (0.1-0.6 ng/ml) in Primary Biliary Cirrhosis study group
Trial: 8857564
Drug: Tacrolimus concentration
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus concentration range (0.3-0.7 ng/ml) in Multiple Sclerosis study group
Trial: 1642347
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (0.027 mg) with 6 ml sodium chloride 0.9% intravenously
Trial: 1642347
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (0.027 mg) with six sprays of sodium chloride 0.9% intranasally
Trial: 6424496
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition via central veins (Control)
Trial: 17652730
Drug: Other antiepileptic
RxNorm normalized name: Other antiepileptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antiepileptic drugs
Trial: 27177240
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low HDL-C (<30 mg/dL)
Trial: 27177240
Drug: Higher HDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HDL-C (≥30 mg/dL)
Trial: 24479409
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I, n = 35)
Trial: 24479409
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of rAd-p53 plus placebo chemotherapy (group II, n = 33)
Trial: 24479409
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of placebo rAd-p53 plus chemotherapy (group III, n = 31)
Trial: 24479409
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of rAd-p53 plus chemotherapy (group I)
Trial: 21208247
Drug: Oxycodone/paracetamol (5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/paracetamol (5/325 mg), four times daily for 3 days
Trial: 21208247
Drug: Oxycodone/paracetamol (5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/paracetamol (5/325 mg)
Trial: 20646695
Drug: 12 oz
RxNorm normalized name: Oval Amber 12 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 oz oral sulfate solution (OSS) given in equally divided doses the evening before and the morning of colonoscopy
Trial: 20646695
Drug: 12 oz
RxNorm normalized name: Oval Amber 12 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 oz oral sulfate solution (OSS)
Trial: 20646695
Drug: 4 L
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 L sulfate-free electrolyte lavage solution (SF-ELS)
Trial: 16036344
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin C 100 mg, vitamin E 100 mg, β-carotene 6 mg, selenium 50 µg) for 12 weeks
Trial: 9541437
Drug: Alpha-tocopherol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (50 mg per day)
Trial: 9541437
Drug: Beta-carotene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (20 mg per day)
Trial: 7897161
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg hydroxyzine
Trial: 4823547
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg hydroxyzine
Trial: 4823547
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydroxyzine
Trial: 4823547
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pentobarbital
Trial: 4823547
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg pentobarbital
Trial: 26553084
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) guided antibiotic treatment
Trial: 26553084
Drug: Empiric antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotic therapy (Control)
Trial: 22117987
Drug: Esmolol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (0.5 mg/kg loading dose followed by infusion of 30 μg/kg per min)
Trial: 19857748
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of CD133+ stem cells
Trial: 16835340
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg p.o. bid)
Trial: 16835340
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg p.o. bid)
Trial: 8858786
Drug: Statistical models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statistical models for treatment comparison
Trial: 8858786
Drug: Maximum likelihood
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum likelihood (ML) and restricted maximum likelihood (REML) approaches
Trial: 3433091
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetylsalicylic acid (ASA) and dihydroergotamine (DHE)
Trial: 18326594
Drug: Dietary betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary betaine (approximately 517 mg)
Trial: 18326594
Drug: Supplementary betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplementary betaine (approximately 500 mg)
Trial: 18326594
Drug: High-betain meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-betain meal (approximately 517 mg)
Trial: 18326594
Drug: High-betain and
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-betain and high-choline meal (approximately 517 mg betaine, approximately 622 mg choline)
Trial: 18326594
Drug: Choline supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplement (500 mg)
Trial: 10979637
Drug: Sulpirid monotherapy
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpirid monotherapy (200-450 mg/day)
Trial: 10979637
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (combined treatment with spasmolytic, bacterial and cholagogic drugs)
Trial: 8629624
Drug: Very low-protein
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low-protein diet (0.28 g/kg/d) supplemented with keto acids-amino acids (0.28 g/kg/d)
Trial: 17162142
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.58 g/kg/d)
Trial: 1465791
Drug: Fish-oil administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil administration in cyclosporine-treated patients
Trial: 23920031
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration with lactated Ringer's solution (3 mL/kg/h during the procedure, a 20-mL/kg bolus after the procedure, and 3 mL/kg/h for 8 hours after the procedure)
Trial: 23920031
Drug: Standard hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after procedure)
Trial: 23920031
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration with lactated Ringer's solution
Trial: 23920031
Drug: Standard hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hydration with lactated Ringer's solution
Trial: 20223555
Drug: Azithromycin 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1.5% eye drops, twice daily for 3 days
Trial: 20223555
Drug: Tobramycin 0.3%,
RxNorm normalized name: Tobramycin 0.3%, Dexamethasone 0.1% Ophthalmic drops, suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 0.3%, 1 drop every 2 hours for 2 days, then four times daily for 5 days
Trial: 18715414
Drug: Dinoprostone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (3 mg initially, followed by 3 mg after 6 hours)
Trial: 15983179
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (400-800 IU daily)
Trial: 12072669
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of the digestive tract (SDD) with 400 mg of norfloxacin once daily preoperatively and postoperative treatment with 2 mg of colistin, 1.8 mg of tobramycin, and 10 mg of amphotericin B, four times daily, until postoperative day 30.
Trial: 12072669
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with similar regimen of placebo drugs.
Trial: 9797418
Drug: 5-day cefixime
RxNorm normalized name: (-)-cefixim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day cefixime 400 mg
Trial: 9797418
Drug: 10-day cefixime
RxNorm normalized name: (-)-cefixim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day cefixime 400 mg
Trial: 101296
Drug: Weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly doses of 6-mercaptopurine and methotrexate
Trial: 101296
Drug: Further 3
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further 3 month-doses of intrathecal methotrexate and dexamethasone
Trial: 101296
Drug: Intensification, daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification, daily maintenance, and further intrathecal therapy
Trial: 27072971
Drug: Plasma‐Lyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma‐Lyte A 100 mL (P100 group)
Trial: 27072971
Drug: Plasma‐Lyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma‐Lyte A 250 mL (P250 group)
Trial: 27072971
Drug: Plasma‐Lyte A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma‐Lyte A 500 mL (P500 group)
Trial: 27072971
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 500 mL (N500 group)
Trial: 27072971
Drug: Gelofusine 500
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine 500 mL (G500 group)
Trial: 20637149
Drug: Midazolam (0.1‐0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1‐0.3 mg/kg)
Trial: 20637149
Drug: Diazepam (0.3‐0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.3‐0.5 mg/kg)